健民集团: 健民集团关于董事会完成换届选举及聘任高级管理人员的公告

Core Viewpoint - The announcement details the completion of the board of directors' re-election and the appointment of senior management personnel at Jianmin Pharmaceutical Group Co., Ltd, highlighting the new board composition and management structure [1][2][3]. Board Re-election - The 11th board of directors consists of four non-independent directors: Mr. Wang Siyang, Mr. Yuan Pingdong, Mr. Wang Jun, and Mr. Xu Liang, along with three independent directors: Mr. Guo Yunpei, Mr. Yang Zhi, and Mr. Xin Jinguo, plus employee representative director Mr. Hu Zhenbo, serving a three-year term [1][2]. - Mr. Yuan Pingdong was elected as the chairman of the 11th board of directors [2]. Specialized Committees - The specialized committees of the board were established as follows: - Strategic and Sustainable Development Committee: Members include Yuan Pingdong, Guo Yunpei, Wang Siyang, Wang Jun, and Hu Zhenbo, with Yuan Pingdong as the convener [2]. - Audit Committee: Members include Xin Jinguo, Guo Yunpei, Yang Zhi, Pei Rong, and Xu Liang, with Xin Jinguo as the convener [2]. - Nomination Committee: Members include Guo Yunpei, Yang Zhi, Xin Jinguo, Wang Siyang, and Wang Jun, with Guo Yunpei as the convener [2]. - Compensation and Assessment Committee: Members include Yang Zhi, Guo Yunpei, Xin Jinguo, Yuan Pingdong, and Wang Siyang, with Yang Zhi as the convener [2]. - Independent directors constitute more than half of the audit, nomination, and compensation committees, with Xin Jinguo being a professional accountant [2]. Senior Management Appointments - Mr. Wang Jun was reappointed as the president of the company [2]. - Mr. Huang Zhijun and Mr. Pei Xuejun were reappointed as vice presidents [2]. - Mr. Cheng Chaoyang was reappointed as the financial director [2][3]. - Mr. Zhou Jie was reappointed as the board secretary, and Ms. Cao Hong was reappointed as the securities affairs representative [3]. Cancellation of Supervisory Board - The company will no longer have a supervisory board or supervisors, as approved by the 2025 first extraordinary shareholders' meeting and in accordance with relevant laws and regulations [4].